Diatherix CEO calls biodefense, biotechnology conference 'timely'

HUNTSVILLE, Ala. — Diatherix Laboratories Inc. presented at the Michigan Security Network Homeland Security Market Leadership Conference on Nov. 4 in Dearborn, Mich.

Dennis Grimaud, chairman and CEO of Diatherix, explained the impact of the company's advanced molecular diagnostic testing on bio-preparedness, pandemic response, infectious disease diagnosis and military efforts.

"This conference is especially timely because last week Congress reported the government is failing to properly address the urgent and immediate threat of biological terrorism. If our country were faced with a biological attack, fast and accurate testing would be critical in properly containing the outbreak and properly treating victims," Grimaud said.

"In addition, in light of the current H1N1 pandemic, it was an opportune time to discuss how early, simultaneous detection of the H1N1 strain and bacterial co-infections can help effectively identify and treat those patients at highest risk and control the spread of the virus."

Diatherix uses its proprietary molecular technology, to test for multiple pathogens, both viral and bacterial in a single test. Patient results are available the next day. The company is based at the HudsonAlpha Institute for Biotechnology in Huntsville, Ala.

More than 20 presenters discussed biotechnology and biodefense during the conference.

The Michigan Security Network is a nonprofit organization that serves as a platform to accelerate technology development, investment and jobs in Michigan. This was the organization's first technology conference.

"Our goal is to serve as a market connector, serving a critical role in bringing together technology creators with the businesses and first responders that will use their leading edge advancements to save lives -- whether it's swine flu, new pandemics or biodefense on the battlefield,” said Leslie Touma, MiSN’s CEO and founder.